domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -19,22 +19,28 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 
 ### Additional Evidence (extend)
-*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15*
 
 The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15*
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16*
+
+MASH is projected to become the leading cause of liver transplantation. If GLP-1s can resolve steatohepatitis at 62.9% rate and slow fibrosis progression, this prevents late-stage liver disease requiring transplantation. However, the Value in Health Medicare study showed only $28M MASH savings — surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades. This suggests the economic benefit window extends far beyond typical budget scoring horizons, reinforcing the chronic-use inflationary thesis through 2035.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (extend)
+*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16*
+
+Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo. Meta-analysis confirms GLP-1 RAs significantly improve histologic MASH resolution, decrease liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation. Some hepatoprotective benefits appear at least partly independent of weight loss, suggesting direct liver effects beyond metabolic improvement. Combined with established CV and kidney protection, this adds a third major organ system to the multi-organ protection profile.
+
 ---
 
 Relevant Notes:

inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md

@@ -7,9 +7,13 @@ date: 2025-05-01
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, semaglutide, MASH, NASH, liver-disease, organ-protection]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,11 @@ Phase 3 trial of semaglutide 2.4mg in patients with MASH and moderate or advance
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Third organ-protection pathway (after CV and kidney) strengthens the case that GLP-1s should be evaluated as multi-organ protective agents, not just weight loss drugs
 EXTRACTION HINT: The multi-organ protection thesis may justify reframing the existing GLP-1 claim from a weight-loss-economics frame to a metabolic-disease-prevention frame
+
+
+## Key Facts
+- Semaglutide 2.4mg achieved 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo in Phase 3 trial
+- Meta-analysis shows GLP-1 RAs reduce risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients
+- Resmetirom (Rezdiffra) was approved for MASH in March 2024 as dedicated MASH therapy
+- MASH is projected to become leading cause of liver transplantation
+- Value in Health Medicare study estimated only $28M MASH savings from GLP-1s